Welcome to our dedicated page for NANOVIRICIDES SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NANOVIRICIDES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NANOVIRICIDES's regulatory disclosures and financial reporting.
NanoViricides, Inc. filed Amendment No. 2 to its prospectus supplement for its at-the-market offering, updating the maximum amount available to sell to $0 under its Form S-3 program with D. Boral Capital LLC (formerly EF Hutton) as agent.
The company states it may not currently offer and sell common stock through or to the agent pursuant to the prospectus as amended. This update reflects the Form S-3 General Instruction I.B.6 limitations tied to public float. As of November 10, 2025, public float was $34,719,086, based on 17,359,543 non‑affiliate shares at $2.00 per share. Over the prior 12 months, the company has offered and sold approximately $5,009,140 of common stock under I.B.6.
The company notes that if its public float changes, it may sell up to one‑third of its public float on Form S‑3, subject to the Sales Agreement, and that the I.B.6 cap no longer applies if public float exceeds $75 million.
NanoViricides, Inc. is presenting a definitive proxy for a shareholder meeting that includes the election of one Class I director and discusses director and executive compensation principles. The election requires a plurality vote with only "For" or "Withheld" votes counting and broker non-votes having no effect. The document emphasizes tying executive pay to company performance through annual bonuses and long-term awards that consider financial and individual goals and corporate values. It also discloses non-employee director equity holdings: Dr. Jawadekar 41,536, Mr. Rokita 41,009, and Mr. Zucker 39,786.
NanoViricides, Inc. filed an 8-K disclosing several exhibit-level agreements that were furnished with the report. The filing lists extensions of employment agreements for Anil Diwan and Meeta Vyas, with Meeta Vyas’s extension effective July 1, 2025. It also furnishes credit-and-collateral documents dated September 23, 2025: an amendment to a line of credit, an open-ended promissory note, and an open-ended mortgage deed. The report is signed by Anil Diwan as President and Chairman and dated October 1, 2025.
The filing provides the existence and dates of these agreements but contains no financial tables, amounts, or detailed terms in the provided text. The exhibits indicate personnel continuity at the executive level and new or amended financing arrangements secured on September 23, 2025, but the document fragment does not disclose monetary values, interest rates, collateral descriptions, covenants, or counterparty names beyond what is listed.
NanoViricides, Inc. (NNVC) is a development-stage biopharmaceutical company focused on nanoviricide antiviral drug candidates and has no commercial products or revenue. The filing discloses a net loss of approximately $9.5 million and net cash used in operating activities of about $8.5 million for the year, cash and cash equivalents of approximately $1.6 million at June 30, 2025, and additional ATM equity sales of about $1.25 million through September 24, 2025. Management states substantial doubt about the company’s ability to continue as a going concern absent additional financing and available credit under a $3.0 million line of credit. The company reports ongoing preclinical and clinical activities for NV-387 (multiple Indications including MPox, ARI/SARI, RSV and COVID formulations), license arrangements with milestone and royalty obligations, and reliance on third-party collaborators for trials, manufacturing and commercialization.